Politician trade (House)

Viatris (VTRS): Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a purchase $1K–$15K

Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a purchase of Viatris in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
27 days
Disclosure lag
Traded
Nov 18, 2025
Disclosed
Dec 15, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 4, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 4, 2025, Viatris Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial 8-K”) to report the appointment of David Simmons to the Board of Directors of the Company (the “Board”).”
  2. Aug 27, 2025Insider · Their first buy on recordDirector purchased ~$3K of VTRS shares in the open market
  3. Oct 17, 20255% stakeBlackRock, Inc. reported a passive stake (13G) of 6.6%
  4. Oct 24, 2025Company filing · Form 8-K · Bylaws or charter, Shareholder Director NominationsChanged its bylaws, charter or fiscal year, and set the date for shareholder nominations (and 1 more item)
  5. Nov 3, 2025FDAFDA drug approval: Linagliptin
  6. Nov 3, 2025Insider · Bought outside the usual windowDirector purchased ~$2.2K of VTRS shares in the open market
  7. Nov 6, 2025Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  8. Nov 10, 20255% stakeDAVIS SELECTED ADVISERS reported a passive stake (13G) of 6.7%
  9. Nov 18, 2025 · this disclosureCongressDisclosed purchase of VTRS — reported range $1,001 - $15,000

What came next

  1. Dec 3, 2025FDAFDA drug approval: Macitentan
  2. Dec 12, 2025FDAFDA drug approval: Octreotide Acetate
  3. Jan 29, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 3, 2026, Viatris Inc. (the “Company”) announced that Brian Roman, Chief Legal Officer of the Company, would transition from his role with the Company and cease to serve as Chief Legal Officer effective as of February 9, 2026.”
  4. Feb 4, 20265% stakeDAVIS SELECTED ADVISERS reported a passive stake (13G) of 6.1%
  5. Feb 23, 2026Company filing · Form 8-K · Results, RestructuringAnnounced job cuts, closures or a restructuring, and reported its results (and 1 more item)“On February 26, 2026, the Company announced the results of its EWSR, and as a part of the review, committed to and began implementation of certain restructuring activities.”
  6. Feb 24, 2026FDARecall: Amnesteem (Isotretinoin) Capsules, USP 40 mg, packaged in 3 x 10-Count Prescription Packs, Rx Only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, W…
  7. Mar 5, 2026FDAFDA drug approval: Aprepitant
  8. Mar 17, 2026FDARecall: Xanax XR, alprazolam, extended-release tablets, 3 mg, 60 Tablets bottles, Rx only, Distributed by: Viatris Specialty LLC, Morgantown, WV 06506, U.S.A, Made in…
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Viatris

For Viatris, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VTRS page.

Other recent filings by Rep. Gilbert Ray Cisneros Jr. (CA31)

The full history of Rep. Gilbert Ray Cisneros Jr. (CA31) is on the profile page.

How this filing works

Explore the data

Common questions

Which member of Congress traded Viatris (VTRS) stock, and how much?

Rep. Gilbert Ray Cisneros Jr. (CA31) disclosed a purchase of Viatris in the $1K–$15K range. Reported range, not an exact amount.

When did it happen, and when was it made public?

Traded: Nov 18, 2025. Disclosed: Dec 15, 2025. That is 27 days between the two dates.

Why is the amount a range and not an exact figure?

Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.

Where does this information come from?

From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Viatris recently?

For Viatris, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the VTRS page.

Does this mean VTRS stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Viatris

Everything OQRO holds on this company is on its VTRS page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data